clinics of a regional hospital in southern Taiwan. Outpatients with type 2 diabetes were invited to participate the interviews for measuring QoL. After finishing the TTO exercise for measuring QoL, a semi-structured interview was followed to explore participant's view on the methods and specific attributes for trading off. TTO results were transformed to utility value, and interviews were recorded, transcribed verbatim and analyzed by constant comparison approach to saturation. RESULTS: Of all, 96 of the 100 participants completed the TTO (mean age: 55.8Ϯ11.0 years, 54.2% male) the average utility is 0.692Ϯ0.217, yet most participants (nϭ68, 70.8%) accepted current health status and life expectancy and were reluctant to give up any life years to exchange a full health. At interviews, participants revealed their worries, anxiety, discomfort and disturbances of daily life related to diabetes, but those factors were not considered when trading life year and health status during TTO exercise; instead, satisfaction of life expectancy, child-caring and selfrecognition on values of life were considered. Information provided by healthcare providers, peer supports and religions were found to help patients cope with the disease and improve health-related QoL. CONCLUSIONS: For patients with chronic, stable diabetes, an adaptation process may have diluted the impacts of patients' concerns on health-related QoL, and hence trading on life years and health status is inappropriate to measure QoL utility. Further study is to explore feasibility of TTO at different stages of diabetic complications, and cross-validate between TTO and other utility measures.
OBJECTIVES: Quality-of-life (QoL) is increasingly recognized as an important outcome measure that provides information on the burden of diabetes on the physical, mental and social aspects of patients' health. To pick up disease-related changes in QoL of diabetes patients in Korea, we administered Korean Audit of Diabetes-Dependent Quality-of-Life (KR-ADDQoL) instrument. METHODS: A prospective, observational study was carried out on type 2 diabetic patients from the diabetic clinics of 24 medical centers throughout Korea. A total of 413 diabetic patients aged 40 years and over were assessed for Health-Related QoL (HRQoL). HRQoL was assessed with KR-ADDQoL instrument. RESULTS: Patients with diabetes were 58Ϯ9.7 years old (47.2% female), had diabetes for 7.0Ϯ6.2 years. The mean present QoL was 0.4Ϯ0.97 (range: Ϫ3 [extremely bad] to 3 [excellent] ) and diabetes-dependent QoL was Ϫ1.5Ϯ0.98 (range: Ϫ3 [very much better] to 1 [worse]). Patients with diabetes and those with hypertension reported lower present QoL, compared with diabetes only (0.3Ϯ1.01, 0.6Ϯ0.85; pϭ0.0161). The mean KR-ADDQoL average weighted impact (AWI) score was Ϫ2.4Ϯ1.8. Patients with 15-20 years of diabetes reported significantly worse AWI scores (Ϫ3.7Ϯ1.6) compared with those with 10-15 years (Ϫ1.9Ϯ1.5). A negative impact of diabetes was seen in all the dimensions of KR-ADDQoL. Freedom to eat and people's reaction remained as the most (mean AWI scores: Ϫ4.3Ϯ2.8) and least (Ϫ1.3Ϯ2.1) affected QoL domains, respectively, when weighting was considered. CONCLUSIONS: Type 2 diabetes has a negative impact in HRQoL in the patients studied. The findings highlighted the impact of diabetes on QoL with particular reference to the effects on freedom to eat, and freedom to drink. Our study contributed to the knowledge of QoL in Korean patients with type 2 diabetes by using a diabetes-specific QoL instrument. These findings suggest that the impact of diabetes in QoL among Asian is similar [ADDQoL AWI score in Singaporeans: Ϫ2.6Ϯ1.9].
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PDB50 MEDICATION BELIEFS AMONG LOW-INCOME AFRICAN AMERICANS AND CAUCASIANS WITH DIABETES
Iyer N, Thomas J Purdue University, West Lafayette, IN, USA OBJECTIVES: We assessed medication beliefs and evaluated association between race and medication beliefs among low-income African Americans and Caucasians with diabetes. METHODS: A cross-sectional self-administered written survey of Type 2 diabetes patients was conducted at a primary-care clinic affiliated with a hospital serving an urban population. Inclusion criteria were being 18 years or older, diagnosed with Type 2 diabetes at least 6 months prior to the time of the survey, and taking oral anti-diabetic medication. Exclusion criteria were use of insulin or inability to read and write in English. The survey included the Beliefs about Medications Questionnaire to assess individuals' medication beliefs. Analysis of variance was used to compare differences in medication beliefs across race. RESULTS: Usable responses were obtained from 236 of 397 individuals who satisfied inclusion and exclusion criteria, for a response rate of 59%. The sample was 53% African American, 47% Caucasian, 63% female and 72% had annual household income of less than $25,000. A majority (63%) had at most completed high school education. Mean belief scores for necessity of taking diabetes medications were higher for Caucasians (3.74) than for African Americans (3.49) (pϭ0.0396) after adjusting for age, gender, education, time since diabetes diagnosis, number of medications taken for diabetes and total medications taken for all conditions. Mean scores for perceived harm from medications were higher for African Americans (2.55) than Caucasians (2.29) (pϭ0.0162). Mean scores for perceived overuse of medicines by prescribers were higher for African Americans (3.32) as compared to Caucasians (3.04) (pϭ0.0497). CONCLUSIONS: Small differences in medication beliefs between African Americans and Caucasians were observed after adjusting for other covariates. Exploration of the role of medication beliefs in racial disparities may be informative. OBJECTIVES: Individuals with diabetes type 2 usually show low compliance with secondary prevention measures. Economic theory states that, from the demand side, insurance reduces the incentives for individuals to claim self-protection and hence, increases the ex-ante moral hazard while in the other hand, it selects individuals with lower risk preferences. This analysis aims to determine the net effect of contributory and subsidized insurance on preventive effort in individuals undergoing diabetes in Colombia. METHODS: Using data from the National Health Survey-2007, we selected individuals aged between 18-69 and previously diagnosed with diabetes (n ϭ 1446). We performed an instrumental variables model by treating the choice of insurance as endogenous and using self-employment and the proportion of individuals insured under either contributory and subsidized regimens in the municipality as instruments. In this analysis we present marginal effects. RESULTS: We found evidence that, controlling for all covariates, health insurance increases prevention care in individuals under the Contributory regimen (0.259; SE 0,126) in comparison to uninsured individuals; however, for those enrolled in the Subsidized regimen the results were not significantly different when comparing to uninsured individuals(0.047; SE 0.113). CONCLUSIONS: The internalization of costs by health insurers throughout the life of individuals suffering from diabetes is essential to improve secondary prevention in diabetes in the country. In this case, we found that, unlike the Subsidized Regimen, the more comprehensive benefits plan in the Contributory scheme is likely to increase the cost faced by the insurer, encouraging it to promote preventive activities among individuals with diabetes. This finding has important policy implications given the rapid growth in health care costs to treat diabetes in Colombia. These results are easily inferred for other preventable chronic conditions such as chronic obstructive pulmonary disease, heart disease and hypertension.
PDB51 IMPROVING HEALTH INSURANCE AND PREVENTIVE EFFORT AMONG DIABETIC PATIENTS: THE COLOMBIAN EXPERIENCE
PDB52 A LITERATURE REVIEW OF DIABETES RISK ASSESSMENT TOOLS
Thoopputra T, Li S, Newby D, Schneider J University of Newcastle, Callaghan, NSW, Australia OBJECTIVES: To review the variety of diabetes risk assessment tools and their validity METHODS: An electronic literature search of the EMBASE, MEDLINE, Cochrane library was undertaken using key words 'diabetes risk' and screening or assessment or score or questionnaire, 'diabetes prediction', 'medical screening', and 'health risk assessment' from 1995-2010. References of identified articles were also manually searched. RESULTS: The electronic search retrieved a total of 2168 articles reporting diabetes risk questionnaires. Deletion of duplicates by Endnote and manual culling produced a list of 41 questionnaires developed in 22 countries, with the majority (nϭ26) developed in North America and Europe; the remainder were from Asia (nϭ10), Middle-East (nϭ3), Africa (nϭ1) and Australia(nϭ1). Of the 41 questionnaires, 17 were developed for screening of undiagnosed diabetes and 24 for predicting the risk of developing disease in the next 2-20 years. All identified tools are short questionnaires of 2-16 questions with common variables of diabetes risk factor such as age, gender, waist circumference, BMI, family history of diabetes, history of hypertension or antihypertensive medications being used for risk assessment. While scoring format and cutoff points are diverse across the questionnaires, the overall sensitivity, specificity, area under receiver operating characteristic curve (ROC) ranged from 40-97% and 24-86% and 62-87% respectively. Comparatively speaking, there were more tools developed for predicting the risk of developing disease in recent years. CONCLUSIONS: There is a trend of increasing availability of diabetes prediction tools with the existing diabetes risk assessment tools being generally short questionnaire aiming for ease of use in clinical practice. The overall performance of existing tools showed moderate to high accuracy in their predictive performance. However, there are not enough reports about their application in real-life clinical settings to allow an assessment of their effectiveness in routine practice.
PDB53 PRESCRIBING PATTERN OF ANTIDIABETIC DRUGS IN T2DM PATIENTS TERTIARY CARE HOSPITAL IN INDIA
RESULTS:
A total of 1185 established T2DM patients were assessed. The mean (SD) age was 55 (10) years and mean duration of diabetes (SD) of 10 (7) years. Metformin was the most commonly prescribed drug [827 (70%)], in general followed by insulin [627 (53%)], sulfonylureas [520 (44%)], and pioglitazone [329 (28%)]. A total of 348 (29%) patients received monotherapy and 837 (71%) received combination therapy. The most frequently prescribed monotherapy was insulin [214 (62%)], followed by metformin in 81 (23%), sulfonylurea in 49 (14%) and pioglitazone in 4 (1%) patients. Family history(OR 1.76, 95%CI 1.18, 2.64), diabetes duration (OR 2.62, 95% CI 2.05, 3.36), Hb A1c (OR 1.25, 95%CI 1.01, 1.50), neuropathy(OR 1.57, 95% CI, 1.14, 2.2), nephropathy(OR 1.77, 95% CI 1.40, 2.24), retinopathy (OR 1.97, 95% CI 1.63, 2.40), Coronary Artery Disease (CAD) (OR 1.57, 95% CI, 1.14, 2.2) and diabetic foot t (OR 1.62, 95% CI 1.12, 2.40) were all significantly associated with the insulin therapy. Obese and overweight patients were prescribed oral antidiabetic drugs. [metformin (OR 1.25, 95% CI 1.15, 1.35), sulfonylurea (OR 1.28, 95% CI 1.01, 1.61)]. CONCLUSIONS: This study finding indicates that medication use was consistent with evidence based practice guidelines in T2DM. There was, however, scope for improvement in prescribing, especially in the T2DM patients with complications.
PDB54
USE OF ELECTRONIC MEDICAL RECORDS FOR CLINICAL RESEARCH IN THE MANAGEMENT OF TYPE-2 DIABETES
Kamal KM 1 , Civitarese L 2 1 Duquesne University, Pittsburgh, PA, USA, 2 Preferred Primary Care Physicians, Carnegie, PA, USA OBJECTIVES: There is a growing interest in the use of electronic medical records (EMRs) for clinical research. The study describes a collaborative research project that uses an EMR database to explore the level of diabetic care in patients with type 2 diabetes in a primary care setting. METHODS: A retrospective study was conducted using the GE Centricity electronic medical records (EMR) database of a primary care physicians group. Patients with type 2 diabetes were identified using ICD-9 codes of 250.xx (January 1, 2004 to March 31, 2009 ). Patients Ͼ 18 years of age, with two or more visits with their respective physicians, and having an active status in the database were selected. Demographic characteristics, clinical parameters (HbA1c, LDL, HDL) medication use, and number of office visits were identified. Data was extracted using Microsoft SQL and descriptive statistical analyses were conducted using SPSS version 18.0. RESULTS: The study identified 4,598 patients (mean age: 67ϩ 12.9 years and males: 51.8%) with type 2 diabetes. A total of 24,590 office visits were recorded with a mean of 14.1 visits and 127 days between visits. 3,100 (61.3%) patients had HbA1c levels Ͻ 7; 1,473 (29.1%) patients had levels between 7-9; and 484 (9.6%) patients had levels Ͼ 9. 3,970 (59.2%) patients had LDL below 100 mg/dL and 2,737 (40.8%) had LDL greater than 100 mg/dL. Mean number of active medications were 2.34 and diabetes medications were 1.94. Combination drugs were used the most compared with amino acid derivatives and amylin analogs. CONCLUSIONS: The collaborative research project has been established between clinicians and researchers, a baseline data extraction has been developed and now further study will be necessary to prove that specific interventions in high risk patients, i.e. HbA1c Ͼ 9, can ultimately improve care. 
PDB55 CLINICAL AND ECONOMIC EVALUATION OF A DIABETES MEDICATION MANAGEMENT PROGRAM: 2 YEAR PROGRAM UPDATE
OBJECTIVES:
A central Texas health plan implemented a pharmacist-led diabetes medication management program (MMP) offering co-pay waivers for diabetes related medications and supplies. Medication adherence, diabetic control and healthcare costs were compared between patients enrolled in the MMP and matched control patients. METHODS: Patients were enrolled in the MMP if they had baseline A1C levels Ͼ 7.5% and three years of continuous enrollment throughout the study period ("rolling" enrollment from 7/06-12/08). The enrollees and controls were matched 1:1 by age, gender, baseline A1C, and Charlson comorbidity index (CCI). A1C and adherence (Medication Possession Ratio (MPR)) were measured one year before and two years after implementation. A difference in difference analysis used paired t-tests to compare changes in MPR and A1C. Healthcare costs were analyzed by year, group, types of service, diabetes-related and all-cause claims. RESULTS: 144 patients were enrolled in the MMP for at least two years. Average A1C decreased by 0.8 in controls and 1.5 in MMP patients; the difference between groups was statistically significant (PϽ0.01). While both groups declined in MPR for oral antidiabetic drugs (MMP:10% vs. Control:19%), the difference between the groups was statistically significant (Pϭ0.009). After two years, the average per member per month (PMPM) costs increased by 16% and 36% in MMP and control groups, respectively. The increase was mainly attributable to growth in diabetes-related drug and outpatient claims in the MMP group. Inpatient costs appeared to be the greatest difference between the two groups, decreasing by 38% in the MMP group and increasing by 159% in the control group. CONCLUSIONS: When compared to matched control patients, the MMP showed improved patient clinical and adherence measures. Although two-year PMPM costs increased, the significant difference in inpatient costs indicates a potential for longterm savings.
PDB56
IMPACT OF PHARMACIST MANAGEMENT ON PATIENTS WITH DIABETES ENROLLED IN A RURAL FREE CLINIC
Franklin M, Sease JM, Gerrald KR Presbyterian College School of Pharmacy, Clinton, SC, USA OBJECTIVES: Assess the clinical and economic impact of pharmacist education, monitoring, and management of patients with diabetes mellitus (DM) enrolled in a free clinic that serves a rural indigent population. METHODS: Data from 77 patients continuously enrolled in a newly established pharmacist service were analyzed. Patients were Ն18 years of age, qualified for free care on the basis of income and/or insurance status, and had a diagnosis of DM upon entry. Under a collaborative agreement, pharmacists educated patients on DM, counseled patients on lifestyle modifications, assessed appropriateness of drug therapy, and managed drug therapy for DM and associated comorbid conditions. Clinical impact was measured by changes from baseline in hemoglobin A1c (A1c) levels, blood pressure, and lipid levels over a 12 month period. Using cost estimates published in the literature, economic impact was calculated based upon expected savings per 1% decrease in A1c levels. RESULTS: Mean A1c levels were 10.6% at baseline (SD Ϯ2.5 %). At one year, A1c levels decreased an average of 2.3% (PϽ0.001), and 44.2% of patients had an A1c Յ7%. A significant number of patients achieved A1c goal by one year (PϽ0.0001). Significant decreases in mean values were also noted for systolic blood pressure (SBP) (Pϭ0.02), LDL-cholesterol (P Ͻ0.001), and triglycerides (Pϭ 0.001). A significant number of patients reached a SBP goal Յ130 mmHg (Pϭ0.033), LDLcholesterol Յ100 mg/dL (PϽ0.0001), or triglycerides Յ150 mg/dL (PϽ0.0001). Based on an expected savings of $1,118 per 1% decrease in HbA1C levels, the average savings per patient was $2,600, for a total savings potential of $167,364. CONCLUSIONS: Pharmacist management of patients with DM has the potential to significantly impact clinical outcomes and improve costs of care for patients in underserved rural areas.
PDB57
IMPACT OF A PHARMACIST-BASED DIABETES MANAGEMENT PROGRAM ON ADHERENCE TO MEDICATION FOR DIABETIC PATIENTS
Agrawal R 1 , Sansgiry S 1 , Patel H 1 , Hayes D 1 , Roberson K 2 , James C 3 1 University of Houston, Houston, TX, USA, 2 Texas Pharmacy Association, Austin, TX, USA, 3 AstraZeneca Pharmaceuticals LP, San Antonio, TX, USA OBJECTIVES: Average adherence to therapy in patients with diabetes is only 67.5%. This study aims to evaluate the impact of a pharmacist-based diabetes management program on improving medication adherence among diabetic patients. METHODS: Data collected during a collaborative program in which trained pharmacists provided diabetes management including medication, education and diet and lifestyle modification counseling to diabetic patients was obtained. Medications dispensed before (in 2007) and during (in 2008) the intervention was recorded for the patients receiving the intervention and controls (matched on age Ϯ5 years, HbA1C Ϯ0.1%, gender, and baseline cholesterol levels) as part of this retrospective, longitudinal study. Patients with two or more visits at the participating pharmacies were included in the study. Medication Possession Ratios (MPRs) were calculated for every patient. Analysis involving descriptive statistics and t-tests were performed using SAS version 9.2. RESULTS: A total of 135 cases and 243 controls were included in the study of which 53.3% (nϭ72) and 50.78% (nϭ122) were females, respectively. The mean age (SD) of cases and controls was similar 48.6 (11.4) and 47.4 (13.1) years, respectively. The mean MPR(SD) of cases improved from 3.41(3.7) in 2007 to 5.12(10.7) in 2008 (pϭ0.0902). The MPR(SD) for controls, reduced from 2.96(2.9) in 2007 to 2.16(6.8) in 2008. When the changes in MPR(SD) of every individual were compared cases showed greater change of 1.75(1.4) on an average as compared to 0.015(1.8) for controls(pϭ0.0907). Although not significant (pϭ0.083), the percentage of cases that were non-adherent reduced by around 50% from 8.9% in 2007 to 4.4% in 2008. CONCLUSIONS: Adherence to medication in diabetic patients may be improved thorough a planned pharmacists-based disease management program. Further, longitudinal data may be needed to conclusively indicate the impact of pharmacists based intervention.
PDB58 WHAT IS THE IMPACT OF GENERIC SUBSTITUTION OF ROSIGLITAZONE ON PATIENT OUTCOMES AND TREATMENT COSTS? AN HMO EXPERIENCE
Triki N 1 , Greenberg D 1 , Mossinson D 2 , Shani S 1 1 Ben-Gurion University of the Negev, Beer Sheva, Israel, 2 Maccabi Healthcare Services, Tel Aviv, Israel OBJECTIVES: We assessed the impact of the use of a generic substitute of rosiglitazone (an anti-diabetic drug) on patient outcomes and treatment costs. METHODS: From the Maccabi Healthcare Services computerized databases we identified three groups of diabetic patients: 1. Patients who purchased the branded medication Avandia ® and switched entirely to its' generic substitute Rossini ® (same number of packages and dosage; the intervention group; Nϭ1,632), 2. Patients who switched to Rossini ® partially (different number of packages and/or different dosage; the control group; Nϭ440), and 3. Patients who did not switch to Rossini ® at all (Nϭ897). For each patient we retrospectively obtained and compared the following parameters 6-months prior to, and 6-months following the switch: HbA1c levels, number of medication packages purchased, number of physician visits, hospital and emergency room admissions, and pharmaceutical costs. RESULTS: In patients who switched entirely from Avandia ® to Rossini ® we found a 45% decrease in treatment costs (pϽ0.001), as compared with a 29% decrease in costs in the control group that continued treatment with Avandia ® (pϽ0.001) and 37% decrease (pϽ0.001) in the control group that partially switched to Rossini ® (in the control groups there was a decline in the number of packages that were purchased after the switch). In the intervention group, we observed a reduction of 0.1% in HbA1c levels [from 7.6Ϯ1.3% to 7.5Ϯ1.4% (pϽ0.001)] in comparison to a nonsignificant difference in the two other groups [from 7.9Ϯ1.5% to 7.9Ϯ1.6% (pϭ0.198) and from 7.8Ϯ1.4% to 7.7Ϯ1.7% (pϭ0.261), respectively]. We found a decrease in the number of physician visits, and no difference in the number of hospitalization days
